MDxHealth SA (NASDAQ:MDXH) Short Interest Update

MDxHealth SA (NASDAQ:MDXH) was the target of a significant decline in short interest during the month of June. As of June 30th, there was short interest totaling 33,040 shares, a decline of 68.8% from the June 15th total of 106,013 shares. Approximately 0.1% of the company’s stock are short sold. Based on an average daily trading volume, of 911,575 shares, the short-interest ratio is presently 0.0 days.

Analyst Upgrades and Downgrades

MDXH has been the topic of a number of research analyst reports. BTIG Research reduced their price objective on shares of MDxHealth from $7.00 to $4.00 and set a “buy” rating on the stock in a research note on Thursday, May 14th. Lake Street Capital cut their target price on shares of MDxHealth from $9.00 to $5.00 and set a “buy” rating on the stock in a research note on Thursday, May 14th. TD Cowen restated a “buy” rating and issued a $1.50 target price (down from $7.00) on shares of MDxHealth in a research note on Thursday, May 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MDxHealth in a research report on Friday, March 27th. Finally, William Blair downgraded MDxHealth from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 14th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $4.62.

Hedge Funds Weigh In On MDxHealth

A number of large investors have recently bought and sold shares of MDXH. Jefferies Financial Group Inc. acquired a new position in MDxHealth in the third quarter valued at approximately $53,000. Russell Investments Group Ltd. acquired a new stake in shares of MDxHealth during the 3rd quarter worth approximately $461,000. Kennedy Capital Management LLC bought a new stake in shares of MDxHealth in the 3rd quarter worth approximately $1,826,000. FreeGulliver LLC lifted its holdings in shares of MDxHealth by 104.7% in the 3rd quarter. FreeGulliver LLC now owns 252,894 shares of the company’s stock worth $1,176,000 after purchasing an additional 129,348 shares during the last quarter. Finally, Panoramic Capital LLC acquired a new position in MDxHealth during the 3rd quarter valued at approximately $721,000.

MDxHealth Price Performance

MDXH traded down $0.04 during trading hours on Monday, hitting $0.43. 383,639 shares of the stock were exchanged, compared to its average volume of 463,745. The stock has a market cap of $21.48 million, a price-to-earnings ratio of -0.67 and a beta of 1.43. The stock has a 50-day simple moving average of $0.83 and a 200-day simple moving average of $2.31. MDxHealth has a 12 month low of $0.40 and a 12 month high of $5.33.

MDxHealth (NASDAQ:MDXH) last released its earnings results on Thursday, May 14th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.05). The business had revenue of $23.90 million for the quarter, compared to analysts’ expectations of $30.89 million. Sell-side analysts expect that MDxHealth will post -0.6 EPS for the current year.

About MDxHealth

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.